Managed Care

Apremilast in DMARD-Naïve Patients With Psoriatis Arthritis: PALACE 4 (Phase 3)

Alvin Wells, MD, PhD, of the Rheumatology and Immunotherapy Center in Oak Creek, Wisconsin, says that apremilast, which modulates intracellular inflammatory mediators, produced clinicallly significant improvements in signs and symptoms in treated patients in this 52-week study.